Holen Sie sich die Stockscreener-App
1.32
0.75%
-0.01
Handel nachbörslich:
1.32
Schlusskurs vom Vortag:
$1.33
Offen:
$1.35
24-Stunden-Volumen:
243.08K
Relative Volume:
0.41
Marktkapitalisierung:
$80.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.25M
KGV:
-1.9423
EPS:
-0.6796
Netto-Cashflow:
$-19.95M
1W Leistung:
-0.75%
1M Leistung:
-2.94%
6M Leistung:
-15.38%
1J Leistung:
-11.41%
1-Tages-Spanne:
$1.30
$1.35
1-Wochen-Bereich:
$1.28
$1.46
52-Wochen-Spanne:
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Firmenname
MAIA Biotechnology Inc
Sektor
Branche
Telefon
312 416 8592
Adresse
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.32 | 83.94M | 0 | -24.25M | -19.95M | -0.6796 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
MAIA Biotechnology, Inc. SEC Filing (Aug 31, 2026) - Stock Titan
MAIA Biotechnology Inc. (MAIA) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Maia Biotechnology director Guerrero buys $2,386 in common stock - Investing.com
MAIA (MAIA) Latest: Declines 0.07% to $1.38 in the Latest Session; Chart Watch: the Session Ends Within the Reported Technical Boundaries at the CloseDouble Top - vinanet.vn
MAIA Biotechnology Q3 EPS Forecast Lowered by Diamond Equity - MarketBeat
MAIA (MAIA) Q2 2026 Results: EPS Does Not Reach the Reported Estimate on the Day; Post-Earnings: The Stock Records a 3.28% Increase in the Current UpdatePositive Surprise Momentum - vinanet.vn
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - Yahoo Finance
Centric Wealth Management Takes Position in MAIA Biotechnology, Inc. $MAIA - MarketBeat
Solas Capital discloses 4.9% MAIA Biotechnology (MAIA) stake in Schedule 13G/A - Stock Titan
MAIA Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Biotech Challenges - Vinanet
Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MAIA Biotechnology Q2 Results: EPS misses estimates - scanx.trade
MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q Summary - TradingView
MAIA Biotechnology (MAIA) Projected to Release Earnings on Monday - MarketBeat
MAIA Biotechnology Q1 2026 Earnings: EPS Beats Estimates, No Revenue ReportedDividend Growth Analysis - dars.gov.et
MAIA Biotechnology, Inc. Revenue Breakdown – AMEX:MAIA - TradingView
MAIA|Maia Biotechnology Inc|Price:1.255|Chg%:+0.005 - TradingKey
Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey
MAIA|Maia Biotechnology Inc|Price:1.240|Chg%:-0.040 - TradingKey
Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MAIA Biotechnology (MAIA) Gains 3.23% as Shares Push Toward $1.28 Resistance LevelAnalyst Upgrade Stocks - vinanet.vn
Maia Biotechnology Inc (MAIA) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Maia Biotechnology Inc (MAIA) Valuation: PE, PB & Fair Value Analysis - TradingKey
MAIA|Maia Biotechnology Inc|Price:1.290|Chg%:+0.050 - TradingKey
Maia Biotechnology Inc (MAIA) Cash Flow - TradingKey
MAIA Q1 2026 Earnings: Narrower Loss Beats Estimates, But Stock DeclinesBasic EPS Analysis - vinanet.vn
MAIA Q1 2026 Earnings: Narrower Loss Beats Expectations Amid Pipeline ProgressDividend Cut Risk - vinanet.vn
MAIA Q1 2026 Earnings: EPS Beat on Reduced Net Loss, Stock GainsNet Income Trends - vinanet.vn
MAIA Biotechnology Edges Lower as Support Level Faces TestVol Target Rebalance - Bölüm Sonu Canavarı
MAIA Biotechnology Inc. (MAIA) Slides 1.37% as Stock Tests Key Support LevelEarnings Sentiment - dars.gov.et
Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA) - The Globe and Mail
MAIA Biotechnology Inc. (MAIA) Holds Near Support as Trading Volumes Remain SubduedOption Strike Build - dars.gov.et
Data released by MAIA Biotechnology Inc. show that the combination therapy of its candidate drug Apatganosin with Ximiprilizumab demonstrated an acceptable safety profile in a heavily pre-treated population of patients with advanced solid tumors. - Bitget
Maia Biotechnology Reports Initial Efficacy Data from Phase 2 Thio-101 Part C Expansion Trial in Third-Line Non-Small Cell Lung Cancer - marketscreener.com
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - The Manila Times
MAIA Biotechnology Reports 90.5% Interim Disease Control Rate in Phase 2 THIO-101 Part C for Advanced NSCLC - Quiver Quantitative
MAIA Biotechnology Reports Strong Initial Efficacy Data in - GlobeNewswire
MAIA Biotechnology (MAIA) Faces Selling Pressure as Shares Approach Key SupportIPO Entry Watch - dars.gov.et
MAIA Biotechnology Inc. (MAIA) Rises 3.1% as Shares Approach Key ResistanceVolume Profile - DonanımHaber
Enterprise value to EBITDA forward of MAIA Biotechnology, Inc. – AMEX:MAIA - TradingView
Price to earnings forward of MAIA Biotechnology, Inc. – BOATS:MAIA - TradingView
MAIAMAIA Biotechnology Inc Dividends - Finviz
ETFs Investing in MAIA Biotechnology, Inc. Stocks - TradingView
MAIA Biotechnology (MAIA) director receives grant of 26,982 stock options - Stock Titan
MAIA Biotechnology (MAIA) director awarded 26,355 stock options at $1.44 - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director receives 32,630 stock options grant - Stock Titan
Finanzdaten der MAIA Biotechnology Inc-Aktie (MAIA)
Umsatz
Nettogewinn
Free Cashflow
ENV
MAIA Biotechnology Inc-Aktie (MAIA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Guerrero Ramiro | Director |
Aug 20 '26 |
Buy |
1.37 |
11,899 |
16,302 |
600,117 |
| Vitoc Vlad | Chief Executive Officer |
Jun 01 '26 |
Buy |
1.39 |
72,700 |
100,886 |
976,121 |
| Smith Stan | Director |
Jun 01 '26 |
Buy |
1.34 |
75,000 |
100,200 |
1,519,178 |
| Gryaznov Sergei | Chief Scientific Officer |
Jun 01 '26 |
Buy |
1.34 |
2,000 |
2,690 |
46,511 |
| Smith Stan | Director |
Dec 22 '25 |
Buy |
1.22 |
57,189 |
69,999 |
1,421,478 |
| CHAOUKI STEVEN M | Director |
Dec 22 '25 |
Buy |
1.22 |
40,849 |
49,999 |
151,873 |
| Louie Ngar Yee | Director |
Dec 22 '25 |
Buy |
1.22 |
81,699 |
100,000 |
1,248,888 |
| Smith Stan | Director |
Dec 05 '25 |
Buy |
1.20 |
13,740 |
16,441 |
4,580 |
| Vitoc Vlad | Chief Executive Officer |
Nov 28 '25 |
Buy |
1.14 |
50,000 |
56,830 |
881,421 |
| Vitoc Vlad | Chief Executive Officer |
Nov 26 '25 |
Buy |
1.05 |
22,000 |
23,019 |
853,421 |
0.86%
0.31%
Kapitalisierung:
|
Volumen (24h):